Immunization

Latest Issue of OR Manager
March 2021
Home Personnel > Personnel > Immunization

Durablity of response to COVID-19 mRNA-1273 vaccination

Editor's Note This study led by the National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, finds that vaccinations with mRNA-1273 (Moderna) have the potential to provide durable humoral immunity. This report describes immunogenicity data for mRNA-1273 at 119 days after the first vaccination and 90 days after the second…

Read More

By: Judy Mathias
December 3, 2020
Share

CDC recommends healthcare workers, nursing homes receive COVID-19 vaccines first

Editor's Note The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices, on December 1, recommended prioritizing healthcare workers and residents and workers in long-term-care facilities to be the first recipients of the upcoming COVID-19 vaccines. If CDC director Robert Redfield, MD, approves the recommendations, and the…

Read More

By: Judy Mathias
December 3, 2020
Share

Pfizer/BioNTech COVID-19 vaccine receives UK approval, immunizations start next week

Editor's Note Pfizer/BioNTech received emergency approval from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) on December 2 for its COVID-19 vaccine, making the UK the first country to approve the vaccine, the December 2 BBC News reports. The UK has ordered 40 million doses, and MHRA says the…

Read More

By: Judy Mathias
December 2, 2020
Share

Sponsored Message

First COVID-19 vaccinations expected latter part of December

Editor's Note On November 30, Moderna applied for an emergency use authorization (EUA) from the Food & Drug Administration (FDA) for its COVID-19 vaccine. Moderna’s vaccine was developed in collaboration with researchers at the National Institute of Allergy and Infectious Diseases, where Anthony Fauci, MD, is the director. Moderna is…

Read More

By: Judy Mathias
December 1, 2020
Share

ACS, ASA, AORN call for centralized, coordinated governmental action for COVID-19

Editor's Note In a November 23 letter to federal government leaders, the American College of Surgeons (ACS), American Society of Anesthesiologists (ASA), and Association of periOperative Registered Nurses (AORN) asked officials “to act collectively and quickly in support of hospitals and healthcare providers as they continue to struggle in response…

Read More

By: Judy Mathias
November 30, 2020
Share

Pfizer, BioNTech COVID-19 vaccine 95% effective in final analysis, will seek EUA within days

Editor's Note Just a week after Pfizer revealed an interim analysis showing its COVID-19 vaccine to be more than 90% effective, the company on November 18 released its final efficacy analysis showing the vaccine is 95% effective, and that it protects older people who are most at risk of dying…

Read More

By: Judy Mathias
November 18, 2020
Share

Sponsored Message

Moderna announces 94.5% efficacy for COVID-19 vaccine

Editor's Note Moderna Inc (Cambridge, Massachusetts) on November 16 announced that its vaccine is 94.5% effective at preventing COVID-19. Their analysis of a 30,000-person trial (half received the vaccine and half received a placebo) finds that 90 of the 95 COVID-19 documented cases are in the placebo group. The Moderna announcement…

Read More

By: Judy Mathias
November 16, 2020
Share

Medicare to cover monoclonal antibody COVID-19 treatments

Editor's Note The Centers for Medicare and Medicaid Services (CMS) on November 10 announced that Medicare will cover out-of-pocket costs for monoclonal antibody drugs for COVID-19 during the public health emergency. The agency’s coverage includes Eli Lilly’s bamlanivimab, which recently received an emergency use authorization from the Food and Drug…

Read More

By: Judy Mathias
November 12, 2020
Share

Pfizer, BioNTech COVID-19 vaccine more than 90% effective, EUA application could come next week

Editor's Note Pfizer and BioNTech announced November 9 that their COVID-19 vaccine is more than 90% effective 7 days after the second dose in preventing COVID-19 infection in participants without evidence of prior infection. This means that protection is achieved 28 days after initiation of the vaccination, which consists of…

Read More

By: Judy Mathias
November 9, 2020
Share

CMS: How to prepare for COVID-19 vaccine

Editor's Note The Centers for Medicare and Medicaid Services (CMS) on November 5 released a set of toolkits and enrollment actions to take to administer the COVID-19 vaccine when it’s available. Many Medicare-enrolled providers don’t have to take any actions until the vaccine is available. Some Medicare-enrolled providers must also…

Read More

By: Judy Mathias
November 5, 2020
Share

Get OR Manager Updates

Sign Up Now
Video Spotlight
 
OR Manager Jobs
Live chat by BoldChat